울혈성 심부전(CHF) 치료제 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

The global congestive heart failure drugs market size reached USD 9.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 24.5 Billion by 2033, exhibiting a growth rate (CAGR) of 10.62% during 2025-2033. The rising prevalence of obesity and cardiovascular problems, increasing geriatric population and unhealthy dietary habits represent some of the key factors driving the market.

Congestive heart failure is a medical condition that affects the pumping ability of the heart muscle. It is generally caused by hypertension, coronary artery disease, diabetes, obesity, and excessive alcohol consumption. Its symptoms include shortness of breath while lying down, weakness, fatigue, swelling in the abdomen, feet, and ankles, frequent urination at night, nausea, and difficulty in concentration. It can be prevented by maintaining a healthy weight, staying physically active, and controlling blood pressure and glycemic levels. Besides this, it is controlled using various prescribed drugs that help prevent blood clots, expand blood vessels, strengthen the contractions of the heart, and improve heart functioning. At present, ACE inhibitors, vasodilators, digitalis glycosides, diuretics, and beta-blockers are some of the most prescribed congestive heart failure drugs. Amongst these, ACE inhibitors prevent the formation of angiotensin, which causes blood vessels to constrict, and beta blockers block the actions of certain chemicals.

Presently, the increasing global geriatric population, which is highly susceptible to diabetes and chronic cardiovascular diseases, represents one of the major factors positively influencing the market. In addition, excessive smoking and drinking of alcoholic beverages, coupled with unhealthy dietary habits of individuals, increases the risks of heart problems, which is catalyzing the demand for congestive heart failure drugs across the globe. This, coupled with the rising occurrence of heart problems due to obesity and lack of physical activity, is currently strengthening the growth of the market. Furthermore, the increasing awareness among individuals about the benefits of early diagnosis and treatment of heart disease is creating a positive outlook for the market. Apart from this, the escalating demand for effective drugs and treatment and their approval from authorized agencies offer lucrative growth opportunities to the leading market players. Moreover, initiatives undertaken by governments of various countries to improve healthcare infrastructure and provide optimal care to patients are contributing to the growth of the market. Additionally, the expansion of pharmacies in hospitals and residential areas and the burgeoning e-commerce industry providing easy availability of medicines at affordable rates and the facility of secured online payment methods are expected to propel the growth of the market.

Key Market Segmentation:

Drug Class Insights:

• ACE Inhibitors
• Angiotensin 2 Receptor Blockers
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Inotropes
• Others
• The report has also provided a detailed breakup and analysis of the congestive heart failure drugs market based on the drug class. This includes ACE inhibitors, angiotensin 2 receptor blockers, beta blockers, diuretics, aldosterone antagonists, inotropes, and others. According to the report, ACE inhibitors represented the largest segment.

Route of Administration Insights:

• Oral
• Intravenous

Distribution Channel Insights:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Regional Insights:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (The United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. According to the report, North America was the largest market for congestive heart failure drugs. Some of the factors driving the North America market included the development of healthcare infrastructure, increasing cases of heart failure and the easy availability of technologically advanced devices and innovative drugs.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global congestive heart failure drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG), Novartis AG, etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1. How big is the global congestive heart failure drugs market?
• 2. What is the expected growth rate of the global congestive heart failure drugs market during 2025-2033?
• 3. What are the key factors driving the global congestive heart failure drugs market?
• 4. What has been the impact of COVID-19 on the global congestive heart failure drugs market?
• 5. What is the breakup of the global congestive heart failure drugs market based on the drug class?
• 6. What is the breakup of the global congestive heart failure drugs market based on the route of administration?
• 7. What is the breakup of the global congestive heart failure drugs market based on the distribution channel?
• 8. What are the key regions in the global congestive heart failure drugs market?
• 9. Who are the key players/companies in the global congestive heart failure drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Congestive Heart Failure Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 ACE Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Angiotensin 2 Receptor Blockers
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Beta Blockers
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Diuretics
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Aldosterone Antagonists
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Inotropes
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

• 7.1 Oral
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Intravenous
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AstraZeneca plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Bayer AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Boehringer Ingelheim International GmbH (C.H. Boehringer Sohn Ag & Co. KG)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Novartis AG
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report